Johnson & Johnson (J&J; NYSE: JNJ), a healthcare giant in the U.S., is reportedly winding down its cardiovascular and metabolic pharmaceutical unit, as reported by Endpoints News. Insiders have indicated that J&J has issued notices to its sales, marketing, and medical affairs teams this week. The company has acknowledged the development, stating to a source that “we must adapt and evolve our business in the midst of a complex and rapidly changing external environment.”
This strategic move follows J&J’s restructuring measures, which included the closure of its infectious disease and vaccine unit last year. The current shift primarily impacts the commercial teams of the cardiovascular unit, with less significant effects on research and development activities. Additionally, the U.S. giant rebranded its pharmaceutical unit from Janssen to J&J Innovative Medicine 12 months ago, streamlining its R&D focus to three key therapeutic areas: oncology, immunology, and neuroscience.- Flcube.com
